ArticleScientific reports2025
Sesamol regulates AQP3 and HAS2 via MAPK signaling for skin barrier protection an in vitro and molecular docking study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structural Elucidation and Moisturizing Potential of a Polysaccharide Derived fromMolecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The integrity of the skin barrier is crucial for reducing the risk and managing chronic skin conditions such as photoaging, eczema, and atopic dermatitis. Sesamol, a food-derived compound with strong antioxidant properties, is recognized for its anti-aging and skin-whitening effects. However, its role in skin barrier repair and protection remains insufficiently understood. This study aimed to explore the protective and restorative effects of sesamol on the skin barrier and to identify its potential molecular mechanisms. Our findings revealed that sesamol regulates the expression of aquaporin-3 (AQP3) and hyaluronan synthase 2 (HAS2) in HaCaT keratinocytes through the mitogen-activated protein kinase (MAPK) pathway. Additionally, Cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and cluster of differentiation 44 (CD44) were found to contribute to this regulation, leading to increased hyaluronic acid (HA) secretion. Molecular docking experiments further validated stable interactions between sesamol and key proteins, including MAPK, AQP3, and HAS2. In ultraviolet B (UVB)-induced photoaging HaCaT keratinocyte models, sesamol effectively suppressed hyaluronidase (HYAL) mRNA expression, thereby mitigating HA degradation. Similarly, in tumor necrosis factor-alpha (TNF-α)-induced dermatitis models, transepithelial electrical resistance (TEER) measurements demonstrated that sesamol repaired inflammatory skin barrier damage. Collectively, these findings suggest that sesamol has significant potential to combat photoaging and inflammatory skin disorders by strengthening and protecting the skin barrier.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.